UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000038288
Receipt number R000043643
Scientific Title Comparison of vibegron and mirabegron in the treatment of female over active bladder subjects: A randomized, prospective study
Date of disclosure of the study information 2019/12/01
Last modified on 2023/10/17 10:27:28

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Comparison of vibegron and mirabegron in the treatment of female over active bladder subjects: A randomized, prospective study

Acronym

Comparative study in vibegron and mirabegron

Scientific Title

Comparison of vibegron and mirabegron in the treatment of female over active bladder subjects: A randomized, prospective study

Scientific Title:Acronym

Comparative study in vibegron and mirabegron

Region

Japan


Condition

Condition

overactive bladder

Classification by specialty

Urology

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

to compare the efficacy of vibegron and mirabegron in the treatment of female overactive bladder subjects

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1

Exploratory

Trial characteristics_2

Pragmatic

Developmental phase

Phase IV


Assessment

Primary outcomes

the change of urgency incontinence, daytime urinary frequency, nocturia between vibegron and mirabegron

Key secondary outcomes

th change of OABSS, ICIQ-SF, IPSS and KHQ


Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit

Individual

Blinding

Open -no one is blinded

Control

Active

Stratification

NO

Dynamic allocation

NO

Institution consideration


Blocking

NO

Concealment



Intervention

No. of arms

2

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

the intervention of vibegron as the treatment of overactive bladder

Interventions/Control_2

the intervention of mirabegron as the treatment of overactive bladder

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

50 years-old <=

Age-upper limit


Not applicable

Gender

Female

Key inclusion criteria

total OAB symptom scores (OABSS) of>3, urinary urgency episodes>2 per week, post-menopausal women, and age>50 years.

Key exclusion criteria

Patients were excluded if they received oral anticholinergic agents, alpha1-blockers, antidepressants, or anti-anxiety agents, had obvious neurogenic bladder dysfunction, bladder calculi, or active urinary tract infection, or had severe cardiac disease, renal dysfunction (serum-creatinine > 2 mg/dL), and/or hepatic dysfunction (i.e., aspartate aminotransferase and alanine aminotransferase levels of more than twice the normal value)

Target sample size

100


Research contact person

Name of lead principal investigator

1st name Hirotaka
Middle name
Last name Sato

Organization

Hokusuikai Kinen Hospital

Division name

department of urology

Zip code

3100035

Address

3-2-1, Higashihara-cyo, Mito-city, Ibaraki-ken

TEL

0293033003

Email

hirotakasato911@yahoo.co.jp


Public contact

Name of contact person

1st name Hirotaka
Middle name
Last name Sato

Organization

Hokusuikai Kinen Hospital

Division name

department of urology

Zip code

3100035

Address

3-2-1, Higashiha-cyo, Mito-city, Ibaraki-ken

TEL

0293033003

Homepage URL


Email

hirotakasato911@yahoo.co.jp


Sponsor or person

Institute

Department of urology, Hokusuikai Kinen Hospital

Institute

Department

Personal name



Funding Source

Organization

Department of urology, Hokusuikai Kinen Hospital

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization

Japan


Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Hokusuikai Kinen Hospital

Address

3-2-1, Higashihara-cyo, Mito-city, Ibaraki-ken

Tel

0293033003

Email

kfujidr-hsk@yahoo.co.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2019 Year 12 Month 01 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Open public recruiting

Date of protocol fixation

2019 Year 09 Month 01 Day

Date of IRB

2019 Year 10 Month 03 Day

Anticipated trial start date

2019 Year 12 Month 01 Day

Last follow-up date

2026 Year 12 Month 31 Day

Date of closure to data entry

2027 Year 01 Month 31 Day

Date trial data considered complete

2027 Year 01 Month 31 Day

Date analysis concluded

2027 Year 02 Month 28 Day


Other

Other related information



Management information

Registered date

2019 Year 10 Month 14 Day

Last modified on

2023 Year 10 Month 17 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000043643


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name